Premium
Pembrolizumab may be a new adjuvant treatment following renal cell carcinoma surgery
Author(s) -
Nierengarten Mary Beth
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33925
Subject(s) - medicine , pembrolizumab , placebo , renal cell carcinoma , adverse effect , nephrectomy , interim analysis , surgery , randomization , kidney disease , clinical trial , cancer , kidney , immunotherapy , pathology , alternative medicine